SOPHiA GENETICS (NASDAQ:SOPH) CEO Jurgi Camblong Sells 4,486 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $4.77, for a total transaction of $21,398.22. Following the sale, the chief executive officer directly owned 3,302,839 shares of the company’s stock, valued at approximately $15,754,542.03. This trade represents a 0.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

SOPHiA GENETICS Stock Up 0.2%

Shares of SOPH stock traded up $0.01 on Friday, reaching $4.87. 94,648 shares of the stock were exchanged, compared to its average volume of 208,394. SOPHiA GENETICS SA has a twelve month low of $2.58 and a twelve month high of $5.70. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $333.61 million, a price-to-earnings ratio of -9.55 and a beta of 1.13. The business’s 50 day moving average price is $4.88 and its 200 day moving average price is $4.51.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The business had revenue of $21.71 million for the quarter, compared to analysts’ expectations of $21.20 million. As a group, sell-side analysts expect that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. BTIG Research reissued a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Finally, Guggenheim raised their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS has an average rating of “Hold” and an average target price of $7.00.

Institutional Trading of SOPHiA GENETICS

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in SOPHiA GENETICS during the 4th quarter worth $55,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $54,000. Archon Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after buying an additional 14,342 shares during the period. Renaissance Technologies LLC grew its holdings in shares of SOPHiA GENETICS by 169.5% during the fourth quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock worth $388,000 after buying an additional 52,200 shares during the last quarter. Finally, Polen Capital Management LLC purchased a new position in shares of SOPHiA GENETICS during the fourth quarter worth about $102,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.